Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Other equities analysts have also issued reports about the company. Robert W. Baird increased their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday, March 9th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Truist Financial boosted their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $115.55.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $89.77 on Wednesday. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of -21.90 and a beta of 1.22. Dianthus Therapeutics has a 52 week low of $15.25 and a 52 week high of $92.27. The firm’s 50-day simple moving average is $67.46 and its two-hundred day simple moving average is $49.70.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. Analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Activity at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 114,367 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The SEC filing for this sale provides additional information. Insiders sold 323,021 shares of company stock valued at $26,564,008 over the last ninety days. Company insiders own 8.15% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Virtus Investment Advisers LLC raised its position in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the period. Parkside Financial Bank & Trust raised its stake in Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares during the period. Royal Bank of Canada boosted its position in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics in the fourth quarter worth about $40,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.